Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organisms. Journal Article

Local Library Link: Find It @ Loyola

Authors: Wenzler, E; Lee, M; Wu, TJ; Meyer, KA; Shields, RK; Nguyen, MH; Clancy, CJ; Humphries, RM; Harrington, AT
Article Title: Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organisms.
Abstract: OBJECTIVES: To ensure the accuracy of susceptibility testing methods for ceftazidime/avibactam. METHODS: The performances of the Etest (bioMérieux), 30/20?µg disc (Hardy diagnostics) and 10/4?µg disc (Mast Group) were evaluated against the reference broth microdilution (BMD) method for 102 clinically relevant Gram-negative organisms: 69 ceftazidime- and meropenem-resistant Klebsiella pneumoniae and 33 MDR non-K. pneumoniae. Essential and categorical agreement along with major and very major error rates were determined according to CLSI guidelines. RESULTS: A total of 78% of isolates were susceptible to ceftazidime/avibactam. None of the three methods met the defined equivalency threshold against all 102 organisms. The Etest performed the best, with categorical agreement of 95% and major errors of 6.3%. Against the 69 ceftazidime- and meropenem-resistant K. pneumoniae, only the Etest and the 10/4?µg disc met the equivalency threshold. None of the three methods met equivalency for the 33 MDR isolates. There were no very major errors observed in any analysis. These results were pooled with those from a previous study of 74 carbapenem-resistant Enterobacteriaceae and data from the ceftazidime/avibactam new drug application to define optimal 30/20?µg disc thresholds using the error-rate bound model-based approaches of the diffusion breakpoint estimation testing software. This analysis identified a susceptibility threshold of =19?mm as optimal. CONCLUSIONS: Our data indicate that the Etest is a suitable alternative to BMD for testing ceftazidime/avibactam against ceftazidime- and meropenem-resistant K. pneumoniae. The 30/20?µg discs overestimate resistance and may lead to the use of treatment regimens that are more toxic and less effective.
Journal Title: The Journal of antimicrobial chemotherapy
ISSN: 1460-2091; 0305-7453
Publisher: . Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy  
Date Published: 2019